# A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Source: https://onco.cc/trials/nct05482971/  
OnCo record `nct05482971` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.

## Summary

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET is a phase 2 interventional study registered as NCT05482971 by PharmaEssentia, with 91 participants enrolled, started 2022-09-29 and due to reach its primary completion in 2025-05-09. Interventions recorded: Ropeginterferon alfa-2b-njft (P1101).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05482971
- Phase: 2
- Setting: A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Essential Thrombocythemia
- Sponsor: PharmaEssentia
- Enrolled: 91

## Sources

- ClinicalTrials.gov NCT05482971: https://clinicaltrials.gov/study/NCT05482971

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [Ropeginterferon alfa-2b](https://onco.cc/drugs/ropeginterferon-alfa-2b/)
- companies: [PharmaEssentia](https://onco.cc/companies/pharmaessentia/)

---
JSON: https://onco.cc/api/v1/entities/nct05482971.json